All research
Semaglutide 2026-09-26 PubMed

GLP-1 Receptor Agonists in Epilepsy: Separating Evidence for Antiseizure Activity, Neuroprotection, and Disease Modification.


Summary withdrawn

TitrateLab removes an AI-written study summary when it states findings we cannot trace to the study's own record, or when the study falls outside the compounds we track. Read the original record through the link above.


glp-1r-agonist epilepsy neuroprotection disease-modification semaglutide review
Source: pubmed:42794466 · Ingested Sep 26, 2026